News & Events

• Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
  Published on 2022-11-22
• Genetic Analysis AS announces the outcome of the warrant exercise
  Published on 2022-11-21
• Last day of trading in warrants of series TO 1 is November 14, 2022
  Published on 2022-11-10
• CORRECTION: Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
  Published on 2022-11-09
• Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map[®] in Europe
  Published on 2022-11-07
• Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe
  Published on 2022-11-07
• Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
  Published on 2022-11-02
• Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
  Published on 2022-11-02
• Correction: Interim report January – September 2022
  Published on 2022-11-01
• Interim report January – September 2022
  Published on 2022-11-01
• Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
  Published on 2022-10-27
• Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
  Published on 2022-10-26
• Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
  Published on 2022-10-23
• Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
  Published on 2022-10-19
• Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
  Published on 2022-10-12